Aquaculture health, nutrition and genetics firm Benchmark says its has discovered a significant quantitative trait locus (QTL) for tilapia disease resistance, marking the first time a QTL for disease resistance can be used for commercial breeding.
Through genomic analysis from controlled disease resistance trials, the small region of DNA discovered will be used to select broodstock with high levels of infection resistance.
The Kverva-backed company paved the way for reduced antibiotic treatments and infections with the section of DNA discovery for streptococcus iniae; one of the most critical disease challenges for the species.
